Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 33.13 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 16.85 | Oscillator | Buy |
| Williams %R (14) | -87.45 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.90 (Hist -0.10) | Oscillator | Strong Sell |
| Average Directional Index (14) | 32.39 (+DI 11.5 / -DI 32.5) | Trend | Strong Sell |
| EMA 20 | 13.59 | MA | Strong Sell |
| SMA 20 | 13.75 | MA | Strong Sell |
| EMA 50 | 14.87 | MA | Strong Sell |
| SMA 50 | 15.34 | MA | Strong Sell |
| SMA 200 | 14.08 | MA | Strong Sell |
Current price $11.91
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 22, 26 | Citizens | maintain | Market Outperform | Market Outperform |
| Oct 22, 26 | BMO Capital | maintain | Market Perform | Market Perform |
| Oct 22, 26 | Citigroup | maintain | Neutral | Neutral |
| Oct 22, 26 | JP Morgan | maintain | Underweight | Underweight |
| Oct 22, 26 | Wells Fargo | maintain | Equal Weight | Equal Weight |
| Oct 14, 26 | Truist Securities | maintain | Hold | Hold |
| Oct 5, 26 | BMO Capital | maintain | Market Perform | Market Perform |
| Oct 5, 26 | Citigroup | maintain | Neutral | Neutral |
| Jul 30, 26 | Wells Fargo | maintain | Equal Weight | Equal Weight |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
Stock news · updated daily
Integra LifeSciences remains pressured by operational challenges, but restructuring and a returning CEO offer renewed turnaround potential. IART's Wound Reconstruction business continues to underperform, though upcoming product relaunches and market normalization could drive recovery. Valuation appears undemanding, with EBITDA margin expected to exceed 20% in 2025 and double-digit FCF margins possible by 2028.
Investors who lost money on Integra LifeSciences Holdings Corporation ("Integra" or the "Company") stock may have claims to recover their losses. [url="]Glancy
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Oct 21, 2026 | 0.56 | 0.59 | Beat 5.9% | $411.2M |
| Jul 29, 2026 | 0.48 | 0.56 | Beat 16.5% | $418.8M |
| May 5, 2026 | 0.41 | 0.54 | Beat 31.7% | $391.9M |
| Feb 26, 2026 | 0.79 | 0.83 | Beat 5.1% | $434.9M |
| Oct 30, 2025 | 0.43 | 0.54 | Beat 25.6% | $402.1M |
| Jul 31, 2025 | 0.43 | 0.45 | Beat 4.7% | $415.6M |
| 8-K | Oct 9, 2026 | 2026-10-09 17:26:20 | View |
| 8-K | Oct 2, 2026 | 2026-10-02 08:20:13 | View |
| 3 | Sep 28, 2026 | 2026-09-28 16:55:17 | View |
| 8-K | Sep 8, 2026 | 2026-09-08 06:30:25 | View |
| 4 | Sep 4, 2026 | 2026-09-04 07:56:18 | View |
| SC 13G/A | Aug 13, 2026 | 2026-08-13 16:43:30 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | IART | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 71.0x | -28.8x · sector 20.7x | Elevated |
| Forward P/E (FY26E) | 5.1x | EPS est. 2.34 | Discount |
| Price / Book | 0.9x | 2.0x | Discount |
| Price / Sales | 0.6x | 2.1x | Discount |
| EV / EBITDA | 11.4x | 12.5x | In line |
| Return on equity | 1.2% | — | Weak |
| Gross margin | 52.5% | 57.5% | In line |
| Debt / Equity | 1.88 | 1.24 | Levered |
| Piotroski / Altman Z | 7/9 | Z 1.28 | Distress |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 1, 26 | Caruso Andrea B | officer: CVP & CHRO | 0 | — | |
| Oct 1, 26 |
| Caruso Andrea B |
| officer: CVP & CHRO |
| 4,375 @ $43.39 |
| $189.8K |
| Oct 1, 26 | Caruso Andrea B | officer: CVP & CHRO | 2,634 @ $68.10 | $179.4K |
| Oct 1, 26 | Caruso Andrea B | officer: CVP & CHRO | 2,674 @ $65.11 | $174.1K |
| Oct 1, 26 | Caruso Andrea B | officer: CVP & CHRO | 3,244 @ $52.87 | $171.5K |
| Oct 1, 26 | Caruso Andrea B | officer: CVP & CHRO | 4,634 @ $36.22 | $167.8K |
| Oct 1, 26 | Caruso Andrea B | officer: CVP & CHRO | 6,650 @ $23.95 | $159.3K |
| Sep 17, 26 | Shinn Lesha R | officer: CVP, Chief Legal Officer & Sec | 0 | — |